Latest News

Category: News

See all

Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU 

Events, News,

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage theranostic programs at the 39th Annual European Association of Urology Congress (EAU24), Europe’s largest urological event, being held in Paris (France) from 5-8 April...

Read more

World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Clinical, News,

Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature...

Read more

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent

Clinical, News,

Telix today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX...

Read more

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

Clinical, News,

QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical...

Read more

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

ASX, News,

Telix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure...

Read more

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

ASX, News,

Telix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics...

Read more

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

ASX, News,

Telix today announces its financial results for the financial year ended 31 December 2023....

Read more

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

ASX, News,

Telix today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.)...

Read more

Telix Full Year Results 2023 Investor Webcast Notification

ASX, News,

Telix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February...

Read more

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Clinical, News,

Telix today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA...

Read more